scholarly journals Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

2020 ◽  
Vol 71 (4) ◽  
pp. e1-e36 ◽  
Author(s):  
Charles L Daley ◽  
Jonathan M Iaccarino ◽  
Christoph Lange ◽  
Emmanuelle Cambau ◽  
Richard J Wallace ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Pulmonary Disease ◽  
Healthcare Professionals ◽  
Mycobacterium Abscessus ◽  
Clinical Microbiology Laboratory ◽  
Pulmonary Medicine ◽  
Assessment Development ◽  
Evaluation Approach ◽  
Mycobacterium Xenopi ◽  
Immunodeficiency Virus

Abstract Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

scholarly journals Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

2020 ◽  
Vol 71 (4) ◽  
pp. 905-913 ◽  
Author(s):  
Charles L Daley ◽  
Jonathan M Iaccarino ◽  
Christoph Lange ◽  
Emmanuelle Cambau ◽  
Richard J Wallace ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Pulmonary Disease ◽  
Healthcare Professionals ◽  
Mycobacterium Abscessus ◽  
Clinical Microbiology Laboratory ◽  
Pulmonary Medicine ◽  
Assessment Development ◽  
Evaluation Approach ◽  
Mycobacterium Xenopi ◽  
Immunodeficiency Virus

Abstract Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

scholarly journals Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

2020 ◽  
Vol 56 (1) ◽  
pp. 2000535 ◽  
Author(s):  
Charles L. Daley ◽  
Jonathan M. Iaccarino ◽  
Christoph Lange ◽  
Emmanuelle Cambau ◽  
Richard J. Wallace ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Pulmonary Disease ◽  
Healthcare Professionals ◽  
Mycobacterium Abscessus ◽  
Clinical Microbiology Laboratory ◽  
Pulmonary Medicine ◽  
Assessment Development ◽  
Evaluation Approach ◽  
Mycobacterium Xenopi ◽  
Immunodeficiency Virus

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

Therapy-related issues: infections

2017 ◽  
Author(s):  
Philip Wiffen ◽  
Marc Mitchell ◽  
Melanie Snelling ◽  
Nicola Stoner
Keyword(s):  
Human Immunodeficiency Virus ◽  
Infectious Diseases ◽  
Infection Control ◽  
Antimicrobial Stewardship ◽  
Healthcare Professionals ◽  
Antimicrobial Prophylaxis ◽  
Extensive Review ◽  
Modes Of Action ◽  
Immunodeficiency Virus ◽  
Key Aspects

This chapter outlines information relevant to pharmacists and other healthcare professionals related to microbiology and infectious diseases. Basic microbiology is covered including modes of action of antibacterials and the selection and use of antimicrobials. Key aspects of antimicrobial stewardship (including resistance, antimicrobial prophylaxis, and writing guidelines) and of infection control are covered. The chapter includes an extensive review of the treatment of human immunodeficiency virus and a discussion of key principles in the treatment of tuberculosis.

scholarly journals Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19)

2020 ◽  
Author(s):  
Adarsh Bhimraj ◽  
Rebecca L Morgan ◽  
Amy Hirsch Shumaker ◽  
Valery Lavergne ◽  
Lindsey Baden ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Infectious Diseases ◽  
Healthcare Professionals ◽  
Critical Evaluation ◽  
Evidence Based ◽  
Efficacy And Safety ◽  
Assessment Development ◽  
Guideline Panel ◽  
Grade Approach ◽  
Pharmacologic Therapies

Abstract Background There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. The objective was to develop evidence-based rapid guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. Methods The Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and gray literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Results The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. Conclusions The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much-needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.

scholarly journals Treatment of Mycobacterium abscessus Complex

2018 ◽  
Vol 39 (03) ◽  
pp. 362-376 ◽  
Author(s):  
Kevin Winthrop ◽  
Luke Strnad
Keyword(s):  
Pulmonary Disease ◽  
Lung Resection ◽  
Multidrug Resistant ◽  
Mycobacterium Abscessus ◽  
Pulmonary Medicine ◽  
Transplant Recipients ◽  
Unique Problem ◽  
Mycobacterium Abscessus Complex ◽  
Toxic Drug ◽  
Lung Transplant Recipients

AbstractOf the nontuberculous mycobacteria (NTMs) causing lung disease, members of the Mycobacterium abscessus complex (MABc) present a formidable obstacle to successful management. This challenge starts from a poorly understood pathogenesis, continues with complicated subspecies variation in treatment response, and extends to the multidrug-resistant nature of these organisms. The disease often necessitates the use of intravenous therapy, toxic drug combinations, and, in some cases, lung resection. Like many NTMs, MABc treatment requires prolonged therapy with multiple medications, and pulmonary disease in some subspecies can be impossible to eradicate or cure. This disease also represents a frequent and unique problem in certain populations, including cystic fibrosis and lung transplant recipients, and providers who manage such patients should be familiar with how MABc disease influences management. Because of the rising prevalence of the MABc, especially in patients with complicated underlying pulmonary disease, it is increasingly necessary for infectious diseases and pulmonary medicine clinicians to understand the unique aspects of MABc management and understand when to obtain expert consultation in the care of these patients.

scholarly journals Review of the international clinical practice guidelines for the treatment of lung infections caused by nontuberculous mycobacteria

2021 ◽  
Vol 23 (1) ◽  
pp. 66-91
Author(s):  
A.V. Zhestkov ◽  
Artem V. Lyamin ◽  
D.D. Ismatullin ◽  
A.A. Martinovich ◽  
E.V. Haykina
Keyword(s):  
Infectious Diseases ◽  
Nontuberculous Mycobacteria ◽  
Mycobacterium Abscessus ◽  
European Respiratory Society ◽  
Mycobacterium Abscessus Complex ◽  
Mycobacterium Xenopi ◽  
Lung Infections ◽  
American Society ◽  
Slow Growing ◽  
Fast Growing Species

Non-tuberculous mycobacteria (NTM) include more than 190 species and subspecies. Some NTM species can cause human diseases of the lungs or extrapulmonary infections. The guidelines focus on pulmonary mycobacteriosis in adult patients without cystic fibrosis or HIV infection caused by the most common NTMs, such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among slow-growing NTMs and Mycobacterium abscessus complex among fast-growing species. Experts of American Thoracic Society (ATS), European Respiratory Society (ERS), European Society for Clinical Microbiology and Infectious Diseases (ESCMID), and American Society for Infectious Diseases (IDSA) contributed to the development of the guidelines. A total of 31 evidence-based recommendations are provided for the diagnosis and treatment of NTM-induced lung infections.

scholarly journals Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

2013 ◽  
Vol 58 (1) ◽  
pp. e1-e34 ◽  
Author(s):  
Judith A. Aberg ◽  
Joel E. Gallant ◽  
Khalil G. Ghanem ◽  
Patricia Emmanuel ◽  
Barry S. Zingman ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Hiv Infection ◽  
Healthcare Providers ◽  
Health Problems ◽  
Antiretroviral Drugs ◽  
New Information ◽  
Immunodeficiency Virus ◽  
Care Guidelines ◽  
Evidence Based Guidelines ◽  
Specific Health

Abstract Evidence-based guidelines for the management of persons infected with human immunodeficiency virus (HIV) were prepared by an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America. These updated guidelines replace those published in 2009. The guidelines are intended for use by healthcare providers who care for HIV-infected patients. Since 2009, new antiretroviral drugs and classes have become available, and the prognosis of persons with HIV infection continues to improve. However, with fewer complications and increased survival, HIV-infected persons are increasingly developing common health problems that also affect the general population. Some of these conditions may be related to HIV infection itself or its treatment. HIV-infected persons should be managed and monitored for all relevant age- and sex-specific health problems. New information based on publications from the period 2009–2013 has been incorporated into this document.

scholarly journals Impact of susceptibility to injectable antibiotics on the treatment outcomes of Mycobacterium abscessus pulmonary disease

2021 ◽  
Author(s):  
Youngmok Park ◽  
Yea Eun Park ◽  
Byung Woo Jhun ◽  
Jimyung Park ◽  
Nakwon Kwak ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Pulmonary Disease ◽  
Drug Susceptibility ◽  
Mycobacterium Abscessus ◽  
Beta Lactams ◽  
In Vitro Susceptibility ◽  
Referral Hospitals ◽  
Microbiological Cure ◽  
Culture Conversion

Abstract Objectives Current guidelines recommend a susceptibility-based regimen for Mycobacterium abscessus subspecies abscessus pulmonary disease (MAB-PD), but the evidence is weak. We aimed to investigate the association between treatment outcomes and in vitro drug susceptibility to injectable antibiotics in MAB-PD patients. Methods We enrolled MAB-PD patients treated with intravenous amikacin and beta-lactams for ≥4 weeks at four referral hospitals in Seoul, South Korea. Culture conversion and microbiological cure at one year were evaluated based on susceptibility to injectable antibiotics among patients treated with those antibiotics for ≥ 2 weeks. Results A total of 82 patients were analysed. The mean age was 58.7 years, and 65.9% were women. Sputum culture conversion and microbiological cure were achieved in 52.4% and 41.5% of patients, respectively. Amikacin was the most common agent to which the M. abscessus subspecies abscessus isolates were susceptible (81.7%); 9.8% and 24.0% of the isolates were resistant to cefoxitin and imipenem, respectively. The clarithromycin-inducible resistance (IR) group (n = 65) had a lower microbiological cure rate than the clarithromycin-susceptible group (35.4% vs. 64.7%). The treatment outcomes appeared to be similar regardless of in vitro susceptibility results with regard to intravenous amikacin, cefoxitin, imipenem, and moxifloxacin. In the subgroup analysis of the clarithromycin-IR group, the treatment outcomes did not differ according to antibiotic susceptibility. Conclusions We did not find evidence supporting the use of susceptibility-based treatment with intravenous amikacin and beta-lactams in patients with MAB-PD. Further research would be required.

Sign in / Sign up

Export Citation Format

Share Document